Ivan Tomasic Email & Phone Number

Brisbane, California, United States

- Significant contributions to FDA filings, including MYK-461 (Mavacampten) NDA and MYK-491 (Danicamtiv) IND.- Conducted detailed mechanistic studies on MYK-491 using advanced biophysical techniques (Loaded In-Vitro Motility Assays, optical trap experiments), resolving its mode of action (MOA) compared to other compounds like Omecamtiv Mecarbil.-Led biochemistry efforts for the AB-Crystallin project, expressing/purifying wild-type and mutant forms, developing assays for small molecule screening, and studying chaperone biophysics using steady-state kinetics, MST, ITC, and electron microscopy.-Supported the Lus-1 (lusitropy) project, performing steady-state kinetics and single turnover experiments to drive structure-activity relationship (SAR) efforts.

Brisbane, California, United States

-Served as the biochemistry/biophysics representative for the MYK-224 project from pre-candidate selection through regulatory filing. Conducted all IND-related biochemistry and biophysical characterization, including MOA studies, single turnover stopped-flow experiments, steady-state ATPase kinetics, IC50 determinations, multi-species potency tests, compound binding/reversibility studies, and In-Vitro Motility assays.-Contributed to multiple FDA filings, including full authorship of biochemistry MOA non-clinical reports (NCRs) and biochemical/biophysical sections of both the Investigative Brochure and IND for MYK-224.-Developed and optimized a plate-based Loaded In-Vitro Motility Assay (LIMA) to enhance physiological relevance in compound screenings for B-Cardiac Myosin.-Studied the impact of disease-causing myosin regulatory light chain mutations.-Participated in MyoKardia’s internship program, managing PhD candidates, designing their research projects, and overseeing their work through final presentations.- Data Friday team member and organizer (2015-2020, until the pandemic). Coordinated weekly science/research talks, managing speaker sourcing, scheduling, catering, and annual budgeting.

South San Francisco, California, United States

- Developed a high-throughput In-Vitro Motility screening assay to identify lusitropic modulators of B-Cardiac Myosin for heart disease treatments.- Characterized the biophysical effects and MOA of 2-Deoxy-ATP (dATP) on the chemo-mechanical cycle of B-Cardiac myosin using stopped-flow experiments, steady-state ATPase assays, In-Vitro Motility assays, and skinned cardiac fiber studies.- Presented work at the Biophysical Society (BPS) conference in Los Angeles, 2016, highlighting dATP's potential ability to improve cardiac function.

Boston, Massachusetts, United States

- Built and optimized the site’s high-throughput screening (HTS) platform, including Envision plate readers, liquid handlers, and robotics.-Developed assays for pharmaceutical clients, including a TR-FRET parkin screen assay, and executed a 100K compound small molecule screen.-Investigated Mdm2 (E3 ligase)-mediated ubiquitination of p53 and led the development of several successful related commercial products.- Purified and characterized key proteasome components (26S, 19S, and 20S) from various cell types, contributing to product development.-Led expression, purification, and kinetics studies for Deubiquitinating Enzymes (DUBs), developing commercially successful products.- Optimized protein bioconjugation, purification, and quantification of FRET-labeled di-ubiquitins for DUB screening assays. -Contributed to several scientific posters, mentored new personnel, and effectively managed high-revenue custom biochemistry contracts.

Amherst, Massachusetts, United States

- Investigated lysosomal storage disorders (Fabry and Schindler diseases) to understand how mutations in α-GAL and α-NAGAL enzymes contribute to these conditions using various molecular and structural biology techniques.-Engineered point mutations in the α-GAL enzyme to develop a novel Enzyme Replacement Therapy for Fabry disease, aiming to avoid IgG antibody formation issues associated with existing biotherapeutics.-Cloned, expressed, and purified the α-GAL active site mutant (E203S L206A), optimizing crystallization conditions and solving four ligand-soaked crystal structures to elucidate structure-activity relationships.-Measured Michaelis-Menten kinetics and activity for several recombinant lysosomal enzymes.

Master Of Science - Ms, Biochemistry

Bachelor Of Science - Bs, Biology, General